Background: The stages of melanocytic progression are defined as atypical (dysplastic) nevus, melanoma in situ, melanoma in the radial growth phase (RGP), melanoma in the vertical growth phase (VGP), and melanoma in the metastatic growth phase (MGP). Melanoma in situ and RGP melanoma often develop in contiguous association with atypical nevi. This frequently poses a problem with respect to their early detection. Purthermore, unlike cells obtained from VGP and MGP melanomas, cells derived from melanoma in situ and RGP melanoma do not proliferate in vitro. Thus, compared to the late stages of the disease, less information is available regarding genes expressed in the early stages. Materials and Methods: To determine whether spectral imaging, a recently developed optical imaging technique, can detect melanoma in situ and RGP melanoma arising in melanoma precursor lesions, atypical nevi in patients with a clinical history of melanoma were subjected to noninvasive macroscopic spectral imaging. To determine at what stage in the progression pathway of melanoma genes having important biological functions in VGP and MGP melanomas are activated and expressed, lesions of melanoma in situ were analyzed by immunohistochemistry and in situ hybridization for ex-
pigmentation of atypical nevi, melanoma in situ and RGP melanoma that arise in these melanoma precursor lesions are often difficult to recognize and thus frequently go unnoticed. The application of new optical screening techniques for early detection of melanoma and the identification of genes expressed in the early stages of melanoma development are two important avenues in the pursuit of melanoma prevention. The investigations presented here document that macroscopic spectral imaging has the potential to detect melanoma in its early stage of development and that genes essential for the proliferation and cell adhesion of VGP and MGP melanoma are already expressed in melanoma in situ.
Introduction
Human melanoma exhibits three important features: first, it occurs sporadically in approximately 90% of cases, and is the result of familial predisposition in about 10% of cases; second, both the sporadic and familial forms of melanoma in >60% of all cases evolve in a stepwise fashion; and third, the prognosis for patients with melanoma is directly related to the depth of invasion of the primary lesion at the time of diagnosis. Thus, when diagnosed at an early stage, the patient is often cured by a wide and deep excision of the melanoma. However, once vertical growth phase (VGP) melanoma metastasizes to regional lymph nodes or distant sites, the disease becomes refractory to conventional treatment. For this reason, it is important to explore and implement new noninvasive optical imaging techniques that can detect melanoma in the early stages of development.
Recent advances in the field of optical imaging have led to the development of new noninvasive imaging techniques that are expected to have a major impact on biomedical diagnostics and, thus, disease prevention. One of these recently developed optical imaging techniques is spectral imaging, which is defined as the application of spatially resolved spectroscopic analyses to macroscopic and microscopic samples (1, 2) . To determine whether noninvasive spectral imaging can detect melanoma in situ and radial growth phase (RGP) melanoma that arise in, or in contiguous association with, atypical nevi, we imaged atypical nevi in patients with a clinical history of melanoma. The data presented here provide examples of the capability of macroscopic spectral imaging to detect melanoma in atypical nevocytic lesions.
To gain an understanding of molecular events that govern the onset and progression of melanoma, two Philadelphia, PA) . Polyclonal antibodies to the following proteins and antigens were purchased from commercial suppliers: bFGF was from BioGenex (San Ramon, CA), N-cadherin was from Sigma (St. Louis, MO), and CD3, CD4, CD8, CD31, and S100 were from Dako Corporation (Carpinteria, CA).
Using a biotinylated 470 base pair (bp) human bFGF cDNA fragment and a 140 bp biotinylated human FGFR-1 cDNA probe, in situ hybridizations of snap-frozen, and formalin-fixed/ paraffin-embedded 5-,KM normal skin, nevus, and melanoma sections were performed as previously described (8, 9) .
Results

Macroscopic Spectral Imaging and Histologic Analysis of Melanoma In Situ and RGP Melanoma Arising in Atypical Nevi
Given the dark and variegated pigmentation of atypical nevi, which are the precursors and risk markers of melanoma, it is often difficult for the naked eye to detect melanoma in situ and RGP melanoma developing in, or in contiguous association with, these atypical nevocytic lesions. To implement new noninvasive optical screening techniques that can detect melanoma in its early stages of development, we explored one of the optical imaging techniques developed in recent years.
Spectral imaging, defined as the application of spatially resolved spectroscopic analyses to macroscopic and microscopic samples (1,2), allows a high-resolution spectrum, with intensity as a function of wavelength, to be acquired at each pixel in an image, in any imaging mode (transmitted, reflected or fluorescence light, or luminescence). The result is an image cube that contains spectral as well as spatial information. The spectral information can be used to aid segmentation by classifying each pixel in an image according to its spectral signature. Instead of classifying each pixel absolutely by its unique but composite spectrum, it can be modeled as a linear combination of relevant spectra. Given a library of basic spectra known to be an image, the percentage of each basic spectrum contributing to a pixel can be determined. Using these percentages and the total intensity of a pixel, the contribution of each material from the spectral library to a specific pixel can be quantitatively measured. The result is an image cube that contains both spectral and spatial information. Unlike conventional transmittance and fluorescence microscopy, spectral imaging has the ability to generate qualitative and quantitative multiparameter, high-resolution images at the single-cell level. For example, by application of microscopic spectral imaging, we recently documented expression of Stat transcription factors and their down-regulation in individual melanocytes and keratinocytes of atypical nevi obtained from melanoma patients who were treated for 3 months with systemic low-dose interferon-alpha (IFN-a) (10) .
To (Fig. 1A, f) arising in the atypical nevus (Fig. IA, e) . A year later, macroscopic spectral imaging detected on the back of the same patient (Fig. 1B) Of the other 37 atypical nevi that were subjected to macroscopic spectral imaging, none exhibited a spectrally segregated area(s) that was distinct from the macroscopic spectral profile of the entire nevus. Concordant with this finding, histologic examination of H&E-counterstained sections, prepared from each of these atypical nevi following their excision, did not show evidence of a melanoma in any of these atypical nevocytic lesions. (9, 11, 12) . Furthermore, a molecular study of benign and atypical nevi obtained from patients with a clinical history of melanoma demonstrated expression of bFGF and FGFR-1 in the dermal nevocytes and the stroma of these clinically and histologically distinct types of nevi (8) .
Knowing the status of bFGF/FGFR-1 expression in melanoma precursor lesions and advanced-stage melanomas, the purpose of the present study was to determine the status of expression of these two genes in one of the early stages of melanoma development, e.g., in melanoma in situ. Performing in situ hybridization with a bFGF and an FGFR-1 cDNA probe, and immunohistochemistry with a bFGF and human FGFR-1-specific antibody, we analyzed tissue sections prepared from the melanoma in situ that developed in association with the atypical nevus (Fig. 1A) and, as depicted in Figure 2 , a melanoma in situ located adjacent to a VGP melanoma. Similar to the findings of the immunohistochemistry analyses (data not shown), the results of the in situ hybridization analyses revealed strong cytoplasmic expression of bFGF and FGFR-1 in the melanoma in situ. In fact, as seen in the case of the melanoma in situ located next to the VGP melanoma (Fig. 3A, B) , not only was cytoplasmic staining of bFGF (Fig. 3A, a) and A red-green-blue (RGB) image was derived from the spectral cube of the melanocytic lesion (c). The marked pixels in the RGB image were used to select spectra for classification. In the spectral image (d), the area pseudocolored blue represents the spectrally segregated region containing the melanoma in situ. The H&E-counterstained tissue sections (e) and (f) depict the histology of the atypical nevus (e) and the melanoma in situ (f). (B) RGB and spectral image of a melanoma in situ arising adjacent to a scar from a nevus punch biopsy. An RGB image (a) and a pseudocolored macroscopic spectral image (b) show an area containing a scar and adjacent to it, a melanoma in situ. In the spectral image (b), the spectrally segregated regions assigned the pseudocolor green correspond to tissue sections that were diagnosed by histopathology to contain melanoma in situ. FGFR-1 (Fig. 3B, a) detected in every cell constituting the melanoma in situ but the degree of bFGF/FGFR-1 expression in these cells was comparable to that detected in the cells of the adjacent VGP melanoma (Fig. 3A, b and 3B, b) . The skin surrounding the melanomas (Fig. 3A, c and 3B, c) revealed expression of bFGF (Fig. 3A, c) and FGFR-1 (Fig. 3B, c) predominantly in cells comprising the basal layer. The two major functions of adhesion molecules are to facilitate cell-cell contact and attach cells to the extracellular matrix (ECM). In addition, in tumor development, adhesion molecules play an important role in cell migration, proliferation, differentiation, apoptosis, and immune recognition (13) . A family of adhesion molecules whose expression changes with progression to advanced-stage melanomas are the homophilic cadherins. For example, normal melanocytes express E-cadherin, which mediates their adhesion to the surrounding keratinocytes (14) . In contrast, in vitro and in vivo, expression of E-cadherin in VGP and MGP melanomas appears to be down-regulated (14, 15) , raising the possibility that concomitant with melanocytic progression, loss of E-cadherin expression may help sever adhesion of the melanocytic cells from their surrounding keratinocytes. While E-cadherin is differentially expressed in normal melanocytes as compared to VGP and MGP melanomas, the status of N-cadherin expression in the different stages of melanocytic progression is less clear.
As depicted in Figure 4 , expression of Ncadherin was detected in almost every cell comprising the melanoma in situ (Fig. 4a) and the adjacent VGP melanoma (Fig. 4b) (Fig. 4c) exhibited about 10% staining. In the skin surrounding the four MPG melanomas, expression of N-cadherin was almost exclusively detected in epidermal keratinocytes (data not shown). Similarly, a total of 15 benign and atypical nevi that were probed with the same N-cadherin-specific antibody showed expression of N-cadherin predominantly, if not exclusively, in the keratinocytes of the epidermal compartment (data not shown). Parallel to these studies, we also probed sections of the same skin, nevus, and melanoma specimens with an antibody to the cell-cell adhesion molecule, E-cadherin. Strong expression of Ecadherin was detected in epidermal keratinocytes, to a lesser extent in the epidermal-dermal junction of the benign and atypical nevi, and in the skin surrounding the melanomas. In contrast, the melanoma in situ and VGP and MGP melanoma specimens exhibited little or no staining (data not shown). Thus, our findings are in agreement with the results of previous studies (14, 15) , which documented down-regulation of E-cadherin concordant with progression to advanced-stage melanomas. Among solid malignancies, melanoma, in particular, MGP melanoma, represents one of the most vascularized tumors. To determine whether melanomas in situ compared to VGP and MGP melanomas exhibited differences in the number of blood vessels interspersing and surrounding the tumors, we probed sections from the different tumors and surrounding skin with an antibody to CD31 antigen, which is expressed on vascular endothelial cells (16) . The results of this immunohistochemical analysis demonstrated significantly more blood vessels in VGP (19) and detect head and neck, bladder, and breast tumors (20) . Confocal and multiphoton excitation scanning laser microscopy have been used to visualize cellular and subcellular structures of tissues and organs (2 1,22).
One of the major difficulties with noninvasive optical imaging of pigmented tissue, such as the skin or skin cancers, in particular melanoma, is the high scattering in the visible and nearinfrared range, which significantly reduces image contrast and resolution. Two advanced optical imaging techniques that have yielded the most promising results for visualizing morphological details in normal skin and diagnosing pathological alterations in skin lesions are optical coherence tomography (OCT) (23, 24) and spectral imaging, respectively.
We recently demonstrated the capability of microscopic spectral imaging to document the biological impact of low-dose systemic IFN-treatment on distinct members of the family of Stat transcription factors in melanoma precursor lesions (10) . We now provide the first examples documenting that macroscopic spectral imaging has the capability to detect in vivo melanoma arising in melanocytic precursor lesions. Given these findings, we believe that macroscopic spectral imaging will be one of the optical imaging techniques that, in light of the rising incidence of melanoma worldwide, can effectively address the need for noninvasive characterization of atypical melanocytic lesions at first presentation, i.e., prior to their excision and histologic analysis.
The second and equally important aim of our investigation was to determine whether melanomas in situ compared to VGP and MGP melanomas exhibit differences with respect to molecular, vascular, and immunologic markers. The results of these analyses provided a first indication that bFGF-FGFR-1, a growth factor-growth factor receptor pair whose expression is required for the proliferation of VGP and MGP melanomas (9, 11, 12) , is strongly expressed in melanomas in situ. Likewise, the adhesion molecule N-cadherin, which sustains the cell-cell adhesion of VGP and MGP melanomas, is strongly expressed in melanomas in situ. Furthermore, the number of blood vessels and dendritic cells detected in the melanomas in situ was comparable to the number of blood vessels and dendritic cells seen in the VGP and MGP melanomas examined in this study.
Although it is possible that the findings reported here are limited to the melanomas in situ evaluated in this study and may not be representative of all melanomas in situ, they nevertheless raise an interesting question: are expression and presence of these known genes and antigens as essential for the biological functions of melanomas in situ as they are for VGP and MGP melanomas, or are there other and perhaps unknown genes that govern the biological properties of melanomas in situ, and is it the dysfunction of these genes that is responsible for the progression to advanced-stage melanomas? Since it has not been possible thus far to conduct in vitro studies with cell cultures representing melanoma in situ, the first part of the question remains unanswered. The second part of this question is being addressed by scientific efforts to isolate genes that are differentially expressed in the early, compared to the late, stages of melanoma.
